How big is a big hazard ratio in clinical trials?
DOI:
https://doi.org/10.18203/2349-3259.ijct20232191Keywords:
Hazard ratio, Clinical trial, Effect size, Time-to-event dataAbstract
Background: The hazard ratio has been widely used as an index of effect size in clinical trials for time-to-event data. The use of the Cox proportional hazards models and other hazard centered models is ubiquitous in clinical trials for time-to-event data. The relativity of effect sizes (small, medium, large) has been widely discussed and accepted when comparing magnitude of association for continuous and categorical data, but not yet for time-to-event outcomes.
Methods: We review published hazard ratios, investigate the relationships among HR, relative risk (RR), odds ratio (OR), and Cohen’s d, and calculate the corresponding HRs for given event rate in control group ( ) by adding standard normal deviation with 0.2 (small), 0.5 (medium) and 0.8 (large) to the event rate in the case group ( based on equation .
Results: Our results indicate that HRs are from 1.68 to 1.16 when the event rate of control group moves from 1% to 90%, which are equivalent to Cohen’s d = 0.2 (small). HRs are ranged between 3.43 and 1.43 when the event rate of control group moves from 1% to 90%, which are equivalent to Cohen’s d = 0.5 (medium), HRs are valued between 6.52 and 1.73 when the event rate of control group moves from 1% to 90%, which are equivalent to Cohen’s d = 0.8 (large).
Conclusions: This study provides general guidelines in interpreting the magnitudes of HRs for time-to-event data in clinical trials.
Metrics
References
Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol. 2011;64(12):1311-6.
Pereira TV, Horwitz RI, Ioannidis JP. Empirical evaluation of very large treatment effects of medical interventions. JAMA. 2012;308(16):1676-84.
Wasserstein RL, Schirm AL, Lazar NA. Moving to a world beyond “p < 0.05”. Am Stat. 2021.
Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
Chen H, Cohen P, Chen S. How big is a big odds ratio? Interpreting the magnitudes of odds ratios in epidemiological studies. Commu Stat Simul Comput 2010;39:860-4.
Altman DG, Deeks JJ, Sackett DL. Odds ratios should be avoided when events are common. BMJ. 1998;317(7168):1318.
Prentice RL, Zhao S. Regression Models and Multivariate Life Tables. J Am Stat Assoc. 2021; 116(535):1330-45.
Sashegyi A, Ferry D. On the Interpretation of the Hazard Ratio and Communication of Survival Benefit. Oncologist. 2017;22(4):484-6.
Hernán MA. The hazards of hazard ratios. Epidemiology. 2010;21(1):13-5.
Schemper M. Analysis of survival data with nonproportional hazard functions. Control Clin Trials. 1981;2(2):149-59.
Xu R, O'Quigley J. Estimating average regression effect under non-proportional hazards. Biostatistics. 2000;1(4):423-39.
Wei G, Schaubel DE. Estimating cumulative treatment effects in the presence of nonproportional hazards. Biometrics. 2008;64(3):724-32.
Schemper M, Wakounig S, Heinze G. The estimation of average hazard ratios by weighted Cox regression. Stat Med. 2009;28(19):2473-89.
Blagoev KB, Wilkerson J, Fojo T. Hazard ratios in cancer clinical trials--a primer. Nat Rev Clin Oncol. 2012;9(3):178-83.
Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32(22):2380-5.
Weir IR, Marshall GD, Schneider JI. Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment. Ann Oncol. 2019;30:96-102.
Downloads
Published
How to Cite
Issue
Section
